Anthracyclines are anti-tumor antibiotics that work on the DNA inside cancer cells. These drugs are made from natural products produced by the soil fungus Streptomyces. They keep the cells from ...

The three trials are collectively referred to as the anthracyclines in early breast cancer (ABC) trials. The primary aim of the ABC trials was to determine if TC6 was noninferior to the TaxAC regimens ...

Since their discovery more than 50 years ago, anthracyclines have become the mainstay for the treatment of many cancers. However, anthracyclines are associated with a risk of heart failure ...

For decades, anthracyclines have been the gold standard of treatment for women with breast cancer, but that could be changing. Ever since Dennis J. Slamon, MD, director of clinical/translational ...

Anthracyclines have been found to carry an increased risk of cardiotoxicity as well as secondary leukemia. The addition of taxanes to anthracyclines has improved efficacy in several studies and ...

In addition, it was not powered to identify specific patient subgroups that benefited from treatment with clofarabine or with higher doses of anthracyclines. Nevertheless, it is intriguing that the ...

A retrospective analysis of four phase II trials and one phase III trial evaluated the prognostic impact of adjuvant anthracyclines on the efficacy of first-line epirubicin–paclitaxel regimens.

"Anthracyclines should be considered in patients with high genomic-risk, hormone receptor-positive [HR+], node-negative disease," she concluded. The study added to an ongoing debate about the role ...

Among them were trials providing clear evidence that a class of chemotherapy drugs called anthracyclines, in combination with other drugs, is active against early breast cancers. In particular, the ...